QQ客服 官方微博 反馈留言

	Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging
	Liu, Shengnan; Du, Yang; Ma, He; Liang, Qian; Zhu, Xu; Tian, Jie
刊名	CANCER LETTERS
	2019
卷号	453页码:74-83
关键词	Hepatocellular carcinoma Regorafenib Sorafenib Molecular imaging Therapeutic effects
ISSN号	0304-3835
DOI	10.1016/j.canlet.2019.03.037
URL标识	查看原文
收录类别	SCIE ; PUBMED
WOS记录号	WOS:000467511100007
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/5920336
专题	北京航空航天大学
推荐引用方式 GB/T 7714	Liu, Shengnan,Du, Yang,Ma, He,et al. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging[J]. CANCER LETTERS,2019,453:74-83.
APA	Liu, Shengnan,Du, Yang,Ma, He,Liang, Qian,Zhu, Xu,&Tian, Jie.(2019).Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.CANCER LETTERS,453,74-83.
MLA	Liu, Shengnan,et al."Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging".CANCER LETTERS 453(2019):74-83.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。